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AbstrAct
Objective
To investigate the shape of the causal relation 
between body mass index (BMI) and mortality.
Design
Linear and non-linear mendelian randomisation 
analyses.
setting
Nord-Trøndelag Health (HUNT) Study (Norway) and UK 
Biobank (United Kingdom).
ParticiPants
Middle to early late aged participants of European 
descent: 56 150 from the HUNT Study and 366 385 
from UK Biobank.
Main OutcOMe Measures
All cause and cause specific (cardiovascular, cancer, 
and non-cardiovascular non-cancer) mortality.
results
12 015 and 10 344 participants died during a median 
of 18.5 and 7.0 years of follow-up in the HUNT Study 
and UK Biobank, respectively. Linear mendelian 
randomisation analyses indicated an overall positive 
association between genetically predicted BMI 
and the risk of all cause mortality. An increase of 1 
unit in genetically predicted BMI led to a 5% (95% 
confidence interval 1% to 8%) higher risk of mortality 
in overweight participants (BMI 25.0-29.9) and a 
9% (4% to 14%) higher risk of mortality in obese 
participants (BMI ≥30.0) but a 34% (16% to 48%) 
lower risk in underweight (BMI <18.5) and a 14% (−1% 
to 27%) lower risk in low normal weight participants 
(BMI 18.5-19.9). Non-linear mendelian randomisation 
indicated a J shaped relation between genetically-
predicted BMI and the risk of all cause mortality, 
with the lowest risk at a BMI of around 22-25 for the 
overall sample. Subgroup analyses by smoking status, 
however, suggested an always-increasing relation of 
BMI with mortality in never smokers and a J shaped 
relation in ever smokers.
cOnclusiOns
The previously observed J shaped relation between 
BMI and risk of all cause mortality appears to have 
a causal basis, but subgroup analyses by smoking 
status revealed that the BMI-mortality relation is likely 
comprised of at least two distinct curves, rather than 
one J shaped relation. An increased risk of mortality 
for being underweight was only evident in ever 
smokers.
Introduction
Body mass index (BMI) is a commonly used simple 
measure that combines weight and height to classify 
obesity.1 Over the past decades, the prevalence of 
obesity (defined as a BMI of ≥30.0) has increased 
worldwide.2 Although many studies have suggested 
that obesity increases the risks of several adverse 
health conditions,3 life expectancy during the same 
period has increased.4 Several meta-analyses have 
shown a J shaped relation between BMI and all cause 
mortality, with the lowest point of the curve in the 
normal weight (BMI 18.5-24.9) or even the overweight 
(25.0-29.9) category.5 9 However, observational results, 
even from well designed studies with large numbers of 
participants, can be biased by residual confounding 
and reverse causation. This could explain the increased 
risk of mortality observed in underweight (BMI <18.5) 
people. Therefore, investigating the shape of the causal 
relation between BMI and all cause mortality is of great 
interest.
One approach for investigating this is mendelian 
randomisation, in which the association between a 
disease outcome and genetically predicted values 
of a modifiable risk factor are considered.10 The 
rationale for considering genetically predicted values 
is that the genetic code is fixed at conception and 
is therefore somewhat immune to the influence of 
both confounding and reverse causation. Under the 
assumptions that participants with genetic variants 
WhAt Is AlreAdy knoWn on thIs topIc
Several large observational studies have shown a J shaped relation between 
body mass index (BMI) and all cause mortality
By using genetic variants in a mendelian randomisation approach, the shape of 
the BMI-mortality relation can be estimated in a way that is less susceptible to 
biases from reverse causation or confounding
WhAt thIs study Adds
Our mendelian randomisation analyses revealed a J shaped relation between 
genetically predicted BMI and the risk of all cause mortality risk, with the lowest 
risk at a BMI of around 22-25
Subgroup analyses stratified by smoking status suggested a J shaped relation in 
ever smokers, but an always-increasing relation of BMI with mortality in never 
smokers
In analyses split by cause of mortality (cardiovascular versus cancer versus 
non-cardiovascular non-cancer), a J shaped relation was only found for non-
cardiovascular non-cancer mortality outcomes
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predisposing them to higher levels of the risk factor 
are similar on average to participants with genetic 
variants predisposing them to lower levels of the 
risk factor, and that genetic variants only influence 
the outcome through their association with the risk 
factor (here BMI), mendelian randomisation provides 
unconfounded estimates representing average 
changes in the outcome for lifelong differences in BMI 
values.11 If values of the risk factor can be altered in a 
way that reflects these genetic differences, then these 
estimates have a causal interpretation.12 See Davies 
and colleagues for a recent review of the approach.13
We applied mendelian randomisation to investigate 
the potential causal relation of BMI on all cause 
mortality in two population based prospective cohorts: 
the Norwegian Nord-Trøndelag Health (HUNT) Study 
and UK Biobank. Linear analyses were carried out to 
quantify the average causal effect of a population shift 
in the BMI distribution, and non-linear analyses to 
characterise the shape of the BMI-mortality relation. 
Subgroup analyses were performed stratifying by sex, 
smoking status, and age at risk. We also investigated 
the shape of the relation of BMI with disease specific 
mortality and morbidity.
Methods
the Hunt study
We used data from the second wave (1995-97) of the 
HUNT Study on 65 229 people living in Nord-Trøndelag 
aged 20 and older.14 Participants were followed up 
until 15 April 2015 or their date of death. We excluded 
participants without data on BMI or genetic variants 
for BMI, leaving 56 150 people for analysis. Data on 
baseline variables were collected by self administered 
questionnaires or clinical examination. Trained 
nurses measured height and weight at the clinical 
examination, with the participants wearing light 
clothes and no shoes. Height was measured in whole 
centimetres. Weight was measured to the nearest 0.5 
kg. Genome-wide genotyping was carried out by using 
Illumina HumanCoreExome arrays.
uK biobank
The UK Biobank cohort comprises around 500 000 
people (94% of self reported European ancestry) 
aged 40 to 69 at baseline and recruited between 2006 
and 2010 in 22 assessment centres throughout the 
UK. Participants were followed up until 17 February 
2016 or their date of death.15 The database contains 
genome-wide genotyping of baseline samples from all 
participants, results of clinical examinations, assays of 
biological samples, and detailed information on self 
reported health behaviour, and is supplemented by 
linkage with electronic health records such as hospital 
inpatient data, mortality data, and cancer registries. 
Data on height and weight were collected at baseline 
when participants attended the assessment centre. 
Height was measured in whole centimetres with a Seca 
202 device. Weight was measured to the nearest 0.1 kg.
We performed detailed quality control procedures 
on UK Biobank participants and on genetic variants. 
In total, 366 385 unrelated participants of European 
ancestry were included in the analyses. Further details 
on both studies are provided in the supplementary 
material.
single nucleotide polymorphisms and allele score 
as instrumental variables
We selected 77 single nucleotide polymorphisms as 
candidate instrumental variables for BMI based on 
European sex-combined analyses in a genome-wide 
association study of the GIANT (Genetic Investigation 
of Anthropometric Traits) consortium.16 Two of 
these variants (rs12016871 and rs2033732) were 
not available in the HUNT Study, and a further two 
variants (rs13021737 and rs16951275) were excluded 
from the analyses owing to an association with 
smoking status in the HUNT Study. We calculated an 
externally weighted allele score for each participant by 
multiplying the number of BMI-increasing alleles the 
participant carried by the variant’s association with 
BMI from the GIANT study (see supplementary table 
1) and summing across the remaining 73 variants. 
Overall, the weighted allele score explained 2.0% and 
1.6% of the variance in BMI in the HUNT Study and the 
UK Biobank, respectively, corresponding to F statistics 
of 1121 and 5964.
study design
We performed several mendelian randomisation 
analyses, assessing the association between genetically 
predicted BMI and mortality outcomes or disease 
incidence. When the relation between the exposure 
and the outcome is non-linear, a linear mendelian 
randomisation estimate represents the average 
change in the outcome resulting from a shift in the 
population distribution of the exposure.17 Here, we 
express estimates for each 1 unit increase in BMI. We 
also performed non-linear mendelian randomisation 
analyses to estimate the shape of the association 
between genetically predicted BMI and the outcome.18
Our primary analysis considered all cause mortality 
as the outcome. We also conducted a priori specified 
subgroup analyses considering men and women, never 
smokers and ever smokers, and younger and older 
participants (age at risk <65 years and ≥65 years). In 
addition, we studied associations with cause specific 
mortality events (cardiovascular, cancer, and other) 
and with incident diseases (cardiovascular and cancer) 
in the UK Biobank.
statistical analyses
We calculated linear mendelian randomisation 
estimates for BMI on the risk of mortality by using 
the ratio of coefficients method.19 Linear regression 
was used to estimate the association of the allele 
score with BMI and Cox proportional hazards 
regression to estimate the association of the allele 
score with mortality. We adjusted for age, sex, 
centre (in UK Biobank), and for age-squared (in 
linear regression). Estimates were also calculated 
within categories of residual BMI (<18.5, 18.5-19.9, 
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20.0-24.9, 25.0-29.9, and ≥30.0). This categorisation 
is based on World Health Organization guidelines.1 By 
stratifying on residual BMI, defined as a participant’s 
BMI minus the centred genetic contribution to 
BMI from variants included in the allele score, we 
compared individuals in the population who would 
have similar BMI values (that is, values in the 
same stratum) if they had the same genetic code. 
Stratifying on BMI directly would distort estimates, 
as BMI is on the causal pathway from the genetic 
variants to the outcome. As sensitivity analyses, we 
performed the MR-Egger method,20 with an intercept 
term differing from zero representing evidence of 
directional pleiotropy, and the weighted median 
method,21 which is less sensitive to genetic variants 
having outlying variant-specific causal estimates. 
We also generated a scatterplot as a visual check for 
outliers in the variant-specific causal estimates, as 
such variants might be pleiotropic.
We applied a fractional polynomial method to 
calculate non-linear mendelian randomisation 
estimates of BMI on the risk of all cause mortality.17 
18 Briefly, we divided the sample into 100 stratums 
by using residual BMI. Then we calculated the linear 
mendelian randomisation estimate, referred to as a 
localised average causal effect, in each stratum of the 
population as a ratio of coefficients: the association 
of the allele score with the outcome divided by the 
association of the allele score with the exposure. We 
performed meta-regression of the localised average 
causal effect estimates against the mean of the 
exposure in each stratum in a flexible semiparametric 
framework by using the derivative of fractional 
polynomial models of degrees 1 and 2. Two tests 
for non-linearity are reported: a trend test, which 
assesses for a linear trend among the localised average 
causal effect estimates, and a fractional polynomial 
test, which assesses whether a non-linear model fits 
the localised average causal effect estimates better 
than a linear model. Figure 1 provides an intuitive 
explanation of the method. 
All non-linear comparisons are conducted within 
stratums of the population defined by residual 
BMI, so they only provide meaningful information 
on comparisons within these stratums. Hence we 
encourage focusing on the slope of the BMI-mortality 
relation at different values of the BMI distribution, 
rather than differences that extrapolate across the 
whole range of the distribution. The slope of the graph 
of the BMI-mortality relation is the average causal 
estimate at that value of BMI. A statistically significant 
causal estimate at a particular BMI value is evidenced 
not when the confidence interval for the hazard ratio 
excludes the value 1, but when the slopes of the upper 
and lower bounds of its confidence interval are both 
positive for a positive estimate, or both negative for a 
negative estimate.
All statistical analyses were performed with R 
(version 3.4.3) or Stata/SE 15.1 (StataCorp, College 
Station, TX). The supplementary material provides a 
detailed description of the methods.
Patient and public involvement
No patients were involved in setting the research 
question or the outcome measures, nor were they 
involved in the design or implementation of the study. 
No patients were asked to advise on interpretation or 
writing up of results. There are no plans to disseminate 
the results of the research to study participants or the 
relevant patient community.
results
Table 1 shows the baseline characteristics of the 
participants. Participants in the HUNT Study were 
younger at baseline (mean age 49.6 v 56.7) and had 
a slightly lower mean BMI (26.3 v 27.4) than those 
in the UK Biobank. Distributions of BMI in the HUNT 
Study and UK Biobank were similar and approximately 
normal (supplementary table 2), except there were 
more extremely obese participants in the UK Biobank. 
The HUNT Study had a longer follow-up (median 18.5 
v 7.0 years) and more deaths (12 015 v 10 344). A 
greater proportion of participants in the HUNT Study 
were ever smokers than in the UK Biobank (55.9% v 
46.1%).
linear mendelian randomisation analyses
Table 2 shows that linear mendelian randomisation 
analyses provided some evidence of an overall 
association between genetically predicted BMI and all 
cause mortality, suggesting that increasing the overall 
distribution of BMI in the population by 1 unit would 
lead to an overall increase in the risk of mortality of 
4% (95% confidence interval 2% to 6%). The estimate 
was larger in women than in men for both studies. 
However, opposite directions of association were 
seen between BMI categories, with a 1 unit increase 
in genetically predicted BMI leading to a 5% (95% 
confidence interval 1% to 8%) higher risk of mortality 
in overweight participants (BMI 25.0-29.9) and a 
9% (4% to 14%) higher risk of mortality in obese 
participants (BMI ≥30.0), but a 34% (16% to 48%) 
lower risk in underweight participants (BMI <18.5) and 
a 14% (−1% to 27%) lower risk in low normal weight 
participants (BMI 18.5-19.9) (P value for trend 0.05 in 
HUNT Study, 0.02 in UK Biobank). The MR-Egger test 
did not detect substantial directional pleiotropy (MR-
Egger intercept 0.005, P=0.13 in HUNT Study; −0.002, 
P=0.71 in UK Biobank). The MR-Egger and weighted 
median methods gave similar results to the primary 
linear analysis method in UK Biobank (supplementary 
table 3), and the scatterplot did not identify any 
outlying genetic variants (supplementary fig 1). In the 
HUNT Study, estimates from the robust methods were 
substantially attenuated towards the null. One outlier 
was detected, although omitting this variant from the 
analyses did not materially affect our findings.
non-linear mendelian randomisation analyses
Figure 2 shows that the overall results were similar 
between the HUNT Study and UK Biobank. We observed 
a J shaped relation between genetically predicted 
BMI and all cause mortality. The curved shape of the 
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relation was more pronounced in UK Biobank—with 
higher risk both in underweight participants and in 
overweight or obese participants. The lowest risk for 
the overall population was at a BMI of around 22-23 in 
the HUNT Study and around 25 in UK Biobank. Similar 
results were observed in sensitivity analyses omitting 
participants with a mortality event in the first two years 
of follow-up (supplementary fig 2).
subgroup analyses
Figure 3 shows the analysis split by sex. The slope for 
greater harm of increasing BMI among overweight or 
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Standard (linear) mendelian randomisation compares subgroups of 
people with different numbers of alleles for a given genetic variant. For 
simplicity of explanation, we assume that there is one genetic variant 
that has a uniform effect on body mass index (BMI), and people can have 
either zero copies, one copy, or two copies of the BMI-increasing allele. 
The graph on the right shows the distribution of BMI in each subgroup:
The purple line represents the distribution of BMI for those with zero 
copies of the BMI-increasing allele, the dashed orange line for those with 
one copy, and the dashed magenta line for those with two copies.
Any comparison of the average value of the outcome between these 
three groups represents the average causal effect of a population shi in 
the distribution of BMI for the whole population. See Davies and 
colleagues for an explanation of the mendelian randomisation approach and assumptions required.13
In our method, we divide the population into centiles based on “residual BMI” – the value that a participant’s BMI would take if they had 
zero copies of the BMI-increasing allele. This is to ensure that we are comparing as far as possible like-with-like – all comparisons are 
between participants who, if they had the same genotype, would be in the same centile of the BMI distribution.
In the first centile, we compare the shaded groups, and estimate an average causal effect representing a change in genetically-
predicted BMI for these individuals:
In the second centile, we compare these groups (note the change in average BMI for each genetic group):
and so on. Each comparison gives us a localised average causal effect – representing the average change in the outcome for 
individuals in that centile of the distribution of residual BMI, which we scale to a 1 unit increase in genetically predicted BMI. We also 
divide people into clinically motivated categories, to obtain localised average causal estimates in BMI categories defined by the World 
Health Organization. We then perform a meta-regression of the localised average causal effect estimates from each centile in a flexible 
modelling framework to find the best fit for the overall shape of the BMI-mortality relation. The slope at each point of this curve 
represents the average change in the outcome for a 1 unit increase in genetically-predicted BMI – this is the localised average causal 
effect at the given value of BMI.
Fig 1 | Description of method for estimating shape of body mass index-mortality relation by using genetic variants
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obese participants was more evident in women than in 
men.
Figure 4 shows the analyses stratified by smoking 
status. The shape of the BMI-mortality relation was 
markedly different between never smokers and ever 
smokers. In never smokers, the shape of the dose-
response relation was always-increasing in both studies, 
with no evidence for a harmful effect of reducing BMI 
in underweight participants (supplementary table 
4). The increase in risk of all cause mortality with 
increasing BMI for never smokers was most clear in 
the HUNT Study, with a positive slope throughout 
the underweight, normal weight, and overweight 
categories. In UK Biobank, the shape of the relation 
was similar, although confidence intervals were wide 
and compatible with a null effect at all values of BMI. 
In ever smokers, the relation was J shaped in both 
studies, with a clear detrimental effect of reduced BMI 
in the underweight category and the low normal weight 
category. In severely obese participants in the HUNT 
Study, there was no increased risk of all cause mortality 
associated with higher BMI, possibly owing to fewer 
people having a BMI greater than 35.0. In the analyses 
split by age at risk (supplementary fig 3), the harmful 
effect of low BMI on mortality was clearer in younger 
participants. However, ever smokers comprised a 
considerable proportion of the deaths before age 
65 (75% in HUNT Study and 60% in UK Biobank), 
meaning that differences in the shape of the dose-
response relation between the age categories could be 
explained by smoking status.
Figure 5 shows the analyses for cause specific 
mortality in UK Biobank. The BMI-mortality curve 
for cardiovascular mortality (2145 deaths) was 
increasing, with increased risk associated with a 
higher BMI in the overweight and obese categories, 
no clear evidence for harm of lower BMI in the 
underweight category, and the lowest risk of mortality 
at a BMI of around 21-22. In contrast, the BMI-
mortality curve for cancer mortality (6125 deaths) 
was flatter, with no strong evidence that BMI affects 
cancer mortality in any BMI category. Finally, the 
dose-response relation for other causes of mortality 
(non-cardiovascular non-cancer, 1998 deaths) had 
a profoundly curved J shape, with the lowest risk of 
mortality at a BMI of 23.0-24.0. The main causes of 
death in the “other” group were respiratory diseases 
(27%); diseases of the digestive system, including 
alcoholic liver disease (18%); diseases of the nervous 
system (15%); and deaths from external causes, 
including suicide (11%). In analyses for incident 
diseases in UK Biobank (supplementary fig 4), the 
curve for the relation between BMI and cardiovascular 
disease (7087 events) was increasing but with a much 
shallower slope that was compatible with a null 
effect, while the curve for any cancer (24 667 events) 
was again flat.
Supplementary tables 5 and 6 show information on 
mortality events in subgroups. In the UK Biobank study, 
trend and fractional polynomial tests suggested non-
linear relations overall and in most subgroup analyses, 
but not for never smokers (supplementary table 7). 
Supplementary tables 8 and 9 provide estimates of the 
hazard ratio for centiles of the BMI distribution.
discussion
In this mendelian randomisation study of two large 
prospective population based cohorts, we found an 
overall J shaped relation between genetically predicted 
BMI and the risk of all cause mortality. The lowest 
risk was at a BMI of around 22-25. Risk of mortality 
was increased both in underweight participants and 
in overweight and obese participants. These results 
are similar to those from the most recent and largest 
observational meta-analyses.5-7 However, subgroup 
analyses revealed that the overall shape of the BMI-
mortality relation comprised distinct curves rather 
than being one J shaped relation.
In the analyses stratified by smoking status, the 
BMI-mortality relation was always-increasing in never 
table 2 | linear mendelian randomisation estimates. Hazard ratios for all cause mortality for each 1 unit increase in 
body mass index (bMi)
all cause mortality
Hunt study uK biobank Overall
Hazard ratio  
(95% ci) P value
Hazard ratio  
(95% ci) P value
Hazard ratio  
(95% ci) P value
Overall 1.03 (1.00 to 1.06) 0.09 1.05 (1.02 to 1.09) 0.002 1.04 (1.02 to 1.06) <0.001
Men 1.01 (0.96 to 1.06) 0.75 1.05 (1.01 to 1.10) 0.03 1.04 (1.00 to 1.07) 0.05
Women 1.05 (1.00 to 1.09) 0.03 1.06 (1.01 to 1.11) 0.03 1.05 (1.02 to 1.09) 0.002
Within residual BMI categories:
 Underweight (<18.5) 0.79 (0.56 to 1.13) 0.19 0.57 (0.41 to 0.79) <0.001 0.66 (0.52 to 0.84) <0.001
 Low normal weight (18.5-19.9) 0.90 (0.71 to 1.14) 0.40 0.82 (0.66 to 1.03) 0.09 0.86 (0.73 to 1.01) 0.07
 High normal weight (20.0-24.9) 0.98 (0.93 to 1.04) 0.61 1.00 (0.94 to 1.06) 0.98 0.99 (0.95 to 1.04) 0.07
 Overweight (25.0-29.9) 1.04 (0.99 to 1.09) 0.10 1.05 (1.00 to 1.11) 0.04 1.05 (1.01 to 1.08) 0.01
 Obese (≥30.0) 1.05 (0.98 to 1.13) 0.14 1.11 (1.05 to 1.18) <0.001 1.09 (1.04 to 1.14) <0.001
Trend test NA 0.05 NA 0.02 NA 0.01
NA=not applicable.
table 1 | baseline characteristics of participants in the Hunt study and uK biobank
characteristics Hunt study uK biobank
No of participants 56 150 366 385
No (%) of men 26 447 (47.1) 168 171 (45.9)
Mean (SD) age at baseline (years) 49.6 (16.6) 56.7 (8.0)
No of deaths 12 015 10 344
Mean (SD) body mass index 26.3 (4.1) 27.4 (4.8)
Median follow-up (years) 18.5 7.0
No (%) of ever smokers 31 388 (55.9) 168 903 (46.1)
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smokers with no evidence of harm of lower BMI in 
underweight participants. In contrast, a J shaped (or 
even U shaped) BMI-mortality relation was observed 
in ever smokers, with estimates suggesting a harmful 
effect of lower BMI in the underweight and normal 
weight categories. Similarly, the BMI-mortality relation 
was J shaped or decreasing in younger participants 
(<65 years), but it was generally increasing in older 
participants (>65 years). This is not consistent with 
results of several observational studies in older people, 
in which overweight categories were associated with 
a lower risk of all cause mortality.22 23 There is an 
intrinsic limitation in separating age and smoking 
status, as deaths before age 65 were more common in 
ever smokers.
Another factor that is difficult to separate is cause 
specific mortality, as both never smokers and ever 
smokers and younger and older participants, differed 
substantially in their distributions of cause of death. 
We found an increasing relation between BMI and 
cardiovascular mortality, a null relation for cancer 
mortality, and a steep U shaped relation for non-
cardiovascular non-cancer mortality.
Possible explanations for findings
The mechanisms leading to increased all cause 
mortality might be different in underweight and 
overweight or obese participants. Underweight status—
or its underlying causes, such as malnutrition—could 
lead to decreased immune function and an increased 
risk of infection.24 Underweight people might have an 
increased risk of surgical complications.25 Moreover, 
being underweight is associated with psychological 
disorders. A previous systematic review showed that 
being underweight was associated with an increased 
risk of completed suicide.26 A recent observational 
study reported a J shaped association between BMI 
and all cause mortality and a more profound U shaped 
association between lean body mass and mortality,27 
suggesting that the higher risk of all cause mortality in 
the lower range of BMI might be explained by low lean 
mass rather than low fat mass. Low fat-free mass has 
also been reported to associate more strongly with the 
risk of all cause mortality than low fat mass.28
For a given BMI, women have higher levels of 
subcutaneous adipose tissue and fat mass than 
men,29 which could explain the steeper curve for 
harm of BMI increases in overweight and obese 
women compared with men in both the HUNT Study 
and UK Biobank.
The relation between smoking and obesity is 
complex, with previous evidence showing statistical 
interaction in their relation with mortality consistent 
with competitive antagonism.30 People with higher 
genetically predicted BMI are more likely to be 
smokers.31 However, smoking also reduces body 
weight.32 Increased mortality in underweight smokers 
might be driven by respiratory diseases,33 a ma- 
jor component of non-cardiovascular non-cancer 
mortality. This could explain the differences in the BMI-
mortality relation between ever smokers and never 
smokers, as respiratory diseases are more common in 
ever smokers.
strengths and limitations of this study
Our study explored the shape of the potential causal 
relation between BMI and the risk of all cause 
mortality in a mendelian randomisation framework 
using fractional polynomial methodology. This 
method enables the division of the sample population 
into fine stratums, as stratum specific estimates are 
smoothed to give an overall BMI-mortality curve. A 
fine stratification is crucial to investigate the effect of 
lower BMI in underweight participants (1% to 3% of 
our sample populations).
Our study is limited by the study type. Compared 
with observational studies, mendelian randomisation 
studies are less vulnerable to bias from reverse 
causation and unmeasured confounding, particularly 
relating to confounding factors acting after the genetic 
code is fixed at conception. The genetic variants were 
not associated with important confounders such as 
smoking and socioeconomic status in the HUNT Study. 
The genetic variants might be subject to residual 
confounding or pleiotropy. However, the MR-Egger 
test did not detect substantial directional pleiotropy, 
neither did the MR-Egger or weighted median method 
produce a substantially different result in UK Biobank. 
Our investigation is observational rather than 
interventional, so a more conservative interpretation 
that the results represent unconfounded estimates, 
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rather than causal estimates, could be preferred. 
However, if interventions in BMI can be conceived that 
are equivalent to how the genetic variants influence 
BMI, then a causal interpretation is warranted. Our 
results could be affected by collider bias. Stratifying 
on residual BMI rather than BMI directly avoids bias 
in the overall analysis, but stratifying on smoking 
status leads to collider bias. Given the size of the effect 
of BMI on smoking status previously observed in UK 
Biobank,31 however, the magnitude of collider bias in 
this case is likely to be negligible.34
A further limitation is the possibility of ascertainment 
bias. About 30% of the inhabitants in Nord-Trøndelag 
County did not participate in the HUNT Study, and a 
further 14% of the participants did not have information 
on genotype or BMI and so were excluded from the 
analysis. In UK Biobank, only around 5% of people 
invited to take part were enrolled in the study. In addition 
to potential bias owing to differential selection, this 
means that the UK Biobank results are representative 
of healthier people than the UK population average. 
Genetic variants influence traits across the whole life 
course. Consequently, the associations we observe 
between genetically predicted BMI and mortality cannot 
be attributed to the causal effect of BMI at any particular 
period.35
Finally, our investigation was conducted in middle 
aged to early late aged participants of European descent 
based in Norway and the UK. Our findings might not 
be applicable to less healthy individuals, older people, 
and different nationalities and ethnicities.
conclusions and public health implications
Mendelian randomisation analyses in two population 
based prospective cohort studies suggested that 
population shifts to raise BMI across its distribution 
would lead to an overall increased risk of all cause 
mortality, but that increasing BMI to the normal weight 
category would reduce the risk of all cause mortality 
for underweight participants. The shape of the BMI-
mortality curve was, however, different depending 
on sex, smoking status, age, and cause of death, with 
harm of having low BMI being evident in ever smokers, 
and an always-increasing relation between BMI and 
mortality in never smokers.
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